<DOC>
	<DOCNO>NCT00006046</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody locate tumor cell either kill deliver tumor-killing substance without harm normal cell . PURPOSE : Phase I trial study effectiveness monoclonal antibody therapy treat patient advanced colorectal cancer .</brief_summary>
	<brief_title>Monoclonal Antibody Therapy Treating Patients With Advanced Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine toxicity , maximum tolerate dose , pharmacokinetics monoclonal antibody Hu3S193 patient advance colorectal carcinoma . - Determine immune response patient treat regimen . OUTLINE : This dose escalation study . Patients receive monoclonal antibody Hu3S193 ( MAB Hu3S193 ) IV 30 minute 4 hour weekly 8 week follow 2 week rest . Patients stable respond disease week 10 receive maintenance MAB Hu3S193 weekly . Courses repeat every 8 week absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos MAB Hu3S193 maximum tolerate dose ( MTD ) determine . The MTD define dose precede 3 6 patient experience dose limit toxicity . PROJECTED ACCRUAL : A total 18-30 patient accrue study .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven stage IV colorectal carcinoma Failed refused conventional chemotherapy Lewis Y antigen present 50 % tumor cell Measurable evaluable disease No CNS tumor involvement PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 80100 % Life expectancy : At least 6 week Hematopoietic : Granulocyte count great 1,500/mm^3 Platelet count great 100,000/mm^3 Hepatic : Bilirubin great 1.0 mg/dL Prothrombin time le 1.3 time control Renal : Creatinine great 1.4 mg/dL Cardiovascular : No New York Heart Association class III IV heart disease Other : No serious infection require antibiotic serious illness Not pregnant nursing No history bleed gastric ulcer pancreatitis No diabetes mellitus require insulin Human antimouse antibody ( HAMA ) negative PRIOR CONCURRENT THERAPY : Biologic therapy : No prior mouse monoclonal antibody antibody fragment At least 4 week since prior immunotherapy Chemotherapy : See Disease Characteristics At least 4 week since prior chemotherapy Endocrine therapy : No concurrent steroids antiinflammatory agent Radiotherapy : At least 4 week since prior radiotherapy Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2003</verification_date>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
</DOC>